Total Payments
$135,053
2024 Payments
$56,455
Companies
5
Transactions
119
Medicare Patients
150
Medicare Billing
$21,018
Payment Breakdown by Category
Consulting$112,372 (83.2%)
Travel$15,240 (11.3%)
Other$4,416 (3.3%)
Food & Beverage$3,026 (2.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $112,372 | 36 | 83.2% |
| Travel and Lodging | $15,240 | 41 | 11.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,416 | 2 | 3.3% |
| Food and Beverage | $3,026 | 40 | 2.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amicus Therapeutics, Inc. | $74,558 | 45 | $0 (2024) |
| GENZYME CORPORATION | $53,803 | 67 | $0 (2024) |
| Ipsen Biopharmaceuticals, Inc | $6,604 | 5 | $0 (2024) |
| BioMarin Pharmaceutical Inc. | $45.84 | 1 | $0 (2017) |
| SANOFI-AVENTIS U.S. LLC | $42.24 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $56,455 | 33 | Amicus Therapeutics, Inc. ($34,061) |
| 2023 | $40,283 | 31 | GENZYME CORPORATION ($22,077) |
| 2022 | $15,101 | 12 | Amicus Therapeutics, Inc. ($11,639) |
| 2021 | $5,992 | 4 | Amicus Therapeutics, Inc. ($5,992) |
| 2020 | $6,015 | 3 | Amicus Therapeutics, Inc. ($4,752) |
| 2019 | $5,115 | 15 | GENZYME CORPORATION ($3,982) |
| 2018 | $1,091 | 8 | GENZYME CORPORATION ($1,091) |
| 2017 | $5,002 | 13 | GENZYME CORPORATION ($4,956) |
All Payment Transactions
119 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Amicus Therapeutics, Inc. | POMBILITI (Drug), OPFOLDA | Consulting Fee | Cash or cash equivalent | $2,432.00 | General |
| Category: POMPE DISEASE | ||||||
| 12/07/2024 | Amicus Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,432.00 | General |
| 10/09/2024 | Amicus Therapeutics, Inc. | GALAFOLD (Drug) | Consulting Fee | Cash or cash equivalent | $4,256.00 | General |
| Category: FABRY DISEASE | ||||||
| 10/09/2024 | Amicus Therapeutics, Inc. | GALAFOLD (Drug) | Travel and Lodging | Cash or cash equivalent | $85.56 | General |
| Category: FABRY DISEASE | ||||||
| 09/12/2024 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,456.00 | General |
| 09/07/2024 | Amicus Therapeutics, Inc. | — | Travel and Lodging | Cash or cash equivalent | $2,290.44 | General |
| 09/07/2024 | Amicus Therapeutics, Inc. | — | Travel and Lodging | Cash or cash equivalent | $954.86 | General |
| 09/07/2024 | Amicus Therapeutics, Inc. | — | Travel and Lodging | Cash or cash equivalent | $554.51 | General |
| 09/07/2024 | Amicus Therapeutics, Inc. | — | Travel and Lodging | Cash or cash equivalent | $88.72 | General |
| 09/04/2024 | GENZYME CORPORATION | XENPOZYME (Biological), CEREZYME | Food and Beverage | In-kind items and services | $54.30 | General |
| Category: Genetic Disease | ||||||
| 09/03/2024 | Amicus Therapeutics, Inc. | GALAFOLD (Drug) | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| Category: FABRY DISEASE | ||||||
| 08/22/2024 | Amicus Therapeutics, Inc. | GALAFOLD (Drug) | Consulting Fee | Cash or cash equivalent | $1,824.00 | General |
| Category: FABRY DISEASE | ||||||
| 05/20/2024 | Amicus Therapeutics, Inc. | GALAFOLD (Drug) | Consulting Fee | Cash or cash equivalent | $4,864.00 | General |
| Category: FABRY DISEASE | ||||||
| 05/03/2024 | GENZYME CORPORATION | FABRAZYME (Biological) | Consulting Fee | Cash or cash equivalent | $8,192.00 | General |
| Category: Genetic Disease | ||||||
| 05/03/2024 | GENZYME CORPORATION | FABRAZYME (Biological) | Travel and Lodging | In-kind items and services | $424.70 | General |
| Category: Genetic Disease | ||||||
| 05/03/2024 | GENZYME CORPORATION | FABRAZYME (Biological) | Food and Beverage | In-kind items and services | $383.53 | General |
| Category: Genetic Disease | ||||||
| 05/03/2024 | GENZYME CORPORATION | FABRAZYME (Biological) | Travel and Lodging | In-kind items and services | $183.25 | General |
| Category: Genetic Disease | ||||||
| 05/03/2024 | GENZYME CORPORATION | FABRAZYME (Biological) | Travel and Lodging | In-kind items and services | $140.88 | General |
| Category: Genetic Disease | ||||||
| 05/03/2024 | GENZYME CORPORATION | FABRAZYME (Biological) | Travel and Lodging | Cash or cash equivalent | $81.90 | General |
| Category: Genetic Disease | ||||||
| 04/19/2024 | Ipsen Biopharmaceuticals, Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,960.00 | General |
| 04/15/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $8,289.00 | General |
| 04/15/2024 | GENZYME CORPORATION | — | Travel and Lodging | Cash or cash equivalent | $134.35 | General |
| 03/19/2024 | Amicus Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,256.00 | General |
| 03/13/2024 | Amicus Therapeutics, Inc. | Pombiliti (Drug), Opfolda | Food and Beverage | In-kind items and services | $75.78 | General |
| Category: Pompe Disease | ||||||
| 03/13/2024 | Amicus Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $31.27 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 45 | 50 | $17,921 | $6,252 |
| 2022 | 2 | 41 | 43 | $13,375 | $5,852 |
| 2021 | 2 | 36 | 41 | $12,115 | $5,697 |
| 2020 | 2 | 28 | 30 | $8,895 | $3,216 |
Total Patients
150
Total Services
164
Medicare Billing
$21,018
Procedure Codes
8
All Medicare Procedures & Services
8 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 27 | 27 | $11,741 | $3,722 | 31.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 18 | 23 | $6,180 | $2,530 | 40.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 29 | 29 | $10,295 | $4,337 | 42.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 12 | 14 | $3,080 | $1,515 | 49.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 22 | 22 | $7,935 | $3,320 | 41.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 14 | 19 | $4,180 | $2,377 | 56.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 17 | 17 | $6,035 | $2,061 | 34.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 11 | 13 | $2,860 | $1,156 | 40.4% |
About Dr. Staci Kallish, DO
Dr. Staci Kallish, DO is a Clinical Biochemical Genetics healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/21/2008. The National Provider Identifier (NPI) number assigned to this provider is 1811152796.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Staci Kallish, DO has received a total of $135,053 in payments from pharmaceutical and medical device companies, with $56,455 received in 2024. These payments were reported across 119 transactions from 5 companies. The most common payment nature is "Consulting Fee" ($112,372).
As a Medicare-enrolled provider, Kallish has provided services to 150 Medicare beneficiaries, totaling 164 services with total Medicare billing of $21,018. Data is available for 4 years (2020–2023), covering 8 distinct procedure/service records.
Ad
Practice Information
- Specialty Clinical Biochemical Genetics
- Other Specialties Clinical Genetics (M.D.)
- Location Philadelphia, PA
- Active Since 07/21/2008
- Last Updated 09/13/2019
- Taxonomy Code 207SG0202X
- Entity Type Individual
- NPI Number 1811152796
Products in Payments
- GALAFOLD (Drug) $50,786
- FABRAZYME (Biological) $17,690
- FABRAZYME (Drug) $3,982
- CERDELGA (Drug) $3,815
- POMBILITI (Drug) $2,432
- NO PRODUCT DISCUSSED (Drug) $2,232
- Pombiliti (Drug) $75.78
- XENPOZYME (Biological) $54.30
- Brineura (Biological) $45.84
- NEXVIAZYME (Biological) $15.74
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.